Omeros announces publication in the Journal of Clinical Oncology detailing pivotal trial results for narsoplimab in GCSH-TMA

SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER) today announced the online publication of a manuscript detailing the results of its pivotal study evaluating the efficacy and safety of narsoplimab for the treatment of thrombotic microangiopathy associated with hematopoietic stem cell transplantation (HSCT-TMA), an often fatal complication of stem cell transplantation for which there is no approved treatment. The manuscript – Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation–Associated Thrombotic Microangioopathy – will be published in an upcoming volume of the Journal of Clinical Oncology (JCO) and yesterday was done available online by JCO, the flagship publication of the American Society of Clinical Oncology.

About Omeros Corporation

Omeros is an innovative biopharmaceutical company engaged in the discovery, development and commercialization of small molecule and protein therapeutics for large-market and orphan indications targeting immunological diseases, including complement-mediated diseases and dysfunction-related cancers. of the immune system, as well as addictive diseases and compulsive disorders. Omeros’ lead MASP-2 inhibitor, narsoplimab, targets the lectin complement pathway and is the subject of a pending FDA Biologics License Application for the treatment of thrombotic microangiopathy associated with hematopoietic stem cell transplantation. Narsoplimab is also part of several late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome, and COVID-19. OMS906, Omeros’ inhibitor of MASP-3, the key activator of the alternative complement pathway, is launching a Phase 1b clinical program in paroxysmal nocturnal hemoglobinuria (PNH). In addition to its supplement franchise, Omeros has ongoing cutting-edge programs in addiction treatments, immuno-oncology therapies, and adoptive T-cell and human CAR-T therapy systems. More information about Omeros and its programs is available at and in the annual, quarterly and current reports of Omeros filed with the United States Securities and Exchange Commission (SEC), accessible at under “Investors & News — Financial Information — SEC Filings” and on the SEC’s website at

Comments are closed.